3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
5
Sarcoma
2
Conditions
Sarcoma
3
Lung Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
128
Radiotherapy
85
Bevacizumab
43
Radiation
30
Carmustine
29
Irinotecan
25
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
sargramostim
12
Radiotherapy, Intensity-Modulated
12
Radiotherapy, Conformal
12
Sirolimus
10
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
pembrolizumab
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
Gefitinib
8
motexafin gadolinium
7
aldesleukin
7
Procarbazine
7
Gene Expression Profiling
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Glioblastoma
×
Oncolytic Virotherapy
×
Sarcoma
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled